Brokerages expect Inovio Pharmaceuticals Inc (NASDAQ:INO) to post ($0.24) earnings per share for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Inovio Pharmaceuticals’ earnings. The highest EPS estimate is ($0.20) and the lowest is ($0.29). Inovio Pharmaceuticals reported earnings per share of ($0.30) in the same quarter last year, which suggests a positive year-over-year growth rate of 20%. The company is expected to issue its next quarterly earnings results on Thursday, May 14th.
According to Zacks, analysts expect that Inovio Pharmaceuticals will report full-year earnings of ($0.72) per share for the current financial year, with EPS estimates ranging from ($0.91) to ($0.53). For the next fiscal year, analysts expect that the business will report earnings of ($0.74) per share, with EPS estimates ranging from ($0.83) to ($0.69). Zacks’ EPS averages are an average based on a survey of research analysts that that provide coverage for Inovio Pharmaceuticals.
Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings data on Thursday, March 12th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.14). Inovio Pharmaceuticals had a negative net margin of 2,901.99% and a negative return on equity of 259.07%. The business had revenue of $0.28 million during the quarter, compared to the consensus estimate of $1.36 million. During the same quarter in the previous year, the firm posted ($0.35) EPS.
INO traded up $1.17 during trading on Monday, hitting $8.32. The company’s stock had a trading volume of 35,289,431 shares, compared to its average volume of 62,742,552. The firm’s 50 day moving average price is $5.98 and its two-hundred day moving average price is $3.57. The company has a quick ratio of 2.94, a current ratio of 2.94 and a debt-to-equity ratio of 18.03. Inovio Pharmaceuticals has a 12 month low of $1.91 and a 12 month high of $19.36. The stock has a market capitalization of $1.04 billion, a price-to-earnings ratio of -6.76 and a beta of 2.16.
In related news, CEO Jong Joseph Kim acquired 22,500 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The stock was acquired at an average cost of $3.11 per share, with a total value of $69,975.00. Following the completion of the purchase, the chief executive officer now directly owns 1,100,707 shares in the company, valued at $3,423,198.77. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David B. Weiner sold 3,500 shares of Inovio Pharmaceuticals stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $9.32, for a total value of $32,620.00. Following the sale, the director now directly owns 828,610 shares of the company’s stock, valued at $7,722,645.20. The disclosure for this sale can be found here. 7.90% of the stock is owned by insiders.
Several institutional investors have recently made changes to their positions in INO. ARK Investment Management LLC lifted its holdings in Inovio Pharmaceuticals by 8.6% during the fourth quarter. ARK Investment Management LLC now owns 4,584,966 shares of the biopharmaceutical company’s stock worth $15,130,000 after acquiring an additional 362,276 shares in the last quarter. State Street Corp lifted its holdings in Inovio Pharmaceuticals by 0.4% during the third quarter. State Street Corp now owns 1,744,448 shares of the biopharmaceutical company’s stock worth $3,576,000 after acquiring an additional 6,998 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Inovio Pharmaceuticals by 4.5% during the fourth quarter. Geode Capital Management LLC now owns 1,351,081 shares of the biopharmaceutical company’s stock worth $4,456,000 after acquiring an additional 58,396 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new position in Inovio Pharmaceuticals during the fourth quarter worth about $3,061,000. Finally, Renaissance Technologies LLC lifted its holdings in Inovio Pharmaceuticals by 166.5% during the fourth quarter. Renaissance Technologies LLC now owns 359,500 shares of the biopharmaceutical company’s stock worth $1,186,000 after acquiring an additional 224,600 shares in the last quarter. 33.22% of the stock is owned by institutional investors and hedge funds.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
Recommended Story: Blue-Chip Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.